Lilly stock slips after competitors halt Alzheimer’s plans
Pfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second trial failure. Eli Lilly is developing a similar treatment.
Health Care & Life Sciences
Articles
Governors aside, feds building health care exchanges
The feds may be gaining on GOP governors who've balked at carrying out a key part of the health care overhaul law. Opponents of the law say they won't set up new private health insurance exchanges. But increasingly it's looking like Washington will do it for them.
Despite funding dip, IU bets on brains
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
Next up for Indiana biotech: Feed the world
Even though the potential payoff for health care innovation is less certain these days, the business case for new ways to produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural innovation.
Daniels seeks candidate input on health exchange
Indiana Gov. Mitch Daniels asked the three gubernatorial candidates this week for their input as he decides whether to establish a state health insurance exchange.
Donors slow to support agencies serving seniors despite growing need
The aging population is expected to generate an explosion in demand for senior services—taxing a network of often thinly funded providers. Executives of such not-for-profits say they often encounter apathy toward senior causes.
Lilly studying how dogs sense diabetes in humans
The Indianapolis drugmaker said its scientists are investigating whether dogs' sharp sense of smell allow them to detect changes in human chemistry.
Cautious hospitals trouble Hill-Rom
The investor drubbing sustained by Hill-Rom Holdings Inc. last week stemmed not so much from the new acquisition it announced as from the gloomy outlook in the North American hospital market.
Lilly braces for decline in Europe
Austerity and upheaval in Europe have not hurt Eli Lilly and Co.’s $4 billion-a-year drug business there, but the company is moving forward with plans to survive a coming swoon anyway.
Employee benefits firm plans Indianapolis expansion
Apex Benefits Group plans to invest $1 million and add 25 jobs paying an average of $44 an hour.
McKesson to pay $151M to settle drug-pricing suit
Twenty-nine states, including Indiana, have reached a $151 million settlement in a lawsuit alleging one of the country's largest drug wholesalers inflated prices for hundreds of prescription drugs, officials said Friday.
Health insurers’ anti-fraud bid seeks to ease profit-limit rule
The Obama administration Thursday announced a partnership with the industry in which WellPoint Inc., UnitedHealth Group Inc. and other insurers may try to share more billing data with the government to root out fraud.
Multi-employer health clinic to open downtown
NoviaCare Clinics LLC will open a multi-employer health clinic in downtown Indianapolis this fall, opening the door for smaller employers to add the service to their health benefits.
Cook Medical shelves Midwest expansion plans
Cook Medical Inc. had been planning to open five new manufacturing plants over the next five years in small communities around the Midwest, including Indiana, but has shelved those plans because of the hit it will take from a new U.S. tax on medical devices.
Hill-Rom stock swoons after $400M acquisition
Investors reacted negatively Thursday after medical equipment and hospital bed maker Hill-Rom Holdings Inc. on Wednesday said it was acquiring Aspen Surgical Products for $400 million.
Indiana Blood Center tapping new vein of revenue
Group sees role in cellular therapy as growth area with profit margins higher than core business.
Indiana life sciences companies rethink innovation
Research and development comes under pressure in an age of austerity.
WellPoint shares sink after profit misses analyst estimates
WellPoint Inc. stock fell more than 12 percent Wednesday after the insurer’s quarterly earnings missed analyst estimates and it trimmed its full-year forecast.
Lilly’s quarterly profit falls, but tops analyst expectations
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Potential Alzheimer’s drug fails first of four key trials
Bapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to target a cause for Alzheimer’s, rather than just its symptoms.